Dicer-substrate Publications

Dicer-substrate RNAi methods were developed as a collaborative effort between the laboratory of Prof. John Rossi at the Beckman Research Institute of the City of Hope National Medical Center and IDT. More recently, studies relating to the in vivo use of Dicer-substrate RNAi have been pursued with the laboratory of Prof. Edouard Cantin, also at the Beckman Research Institute of the City of Hope National Medical Center. Studies into interaction of these RNAs with the innate immune system have been pursued with the laboratory of Prof. Bryan Williams, at the Lerner Research Institute of the Cleveland Clinic Foundation and the Monash Institute of Medical Research.

Dore-Savard, L., Roussy, G., Dansereau, M., Collingwood, M., Lennox, K.A., Rose, S.D., Behlke, M.A., Sarret, P. (2008). Central Delivery of Dicer-substrate siRNA: A Direct Application for Pain Research. Molecular Therapy, v. 16, no. 7, 1331-1339.
* Supplement

Rose, S.D., Collingwood, M.A., and Behlke, M.A. (2006) Optimizing knockdown of gene expression using the TriFECTaTM Dicer-substrate RNAi reagent system. Nature Methods, 3:v-vii, DOI:10.1038/NMETH919.

Kim, D.-H., Behlke, M.A., Rose, S.D., Chang, M.-S., Choi, S., and Rossi, J.J. (2005) Synthetic dsRNA dicer substrates enhance RNAi potency and efficacy. Nature Biotechnology, 23:222-226.
* Supplement

Rose, S.D., Kim, D.-H., Amarzguioui, M., Heidel, J.D., Collingwood, M.A., Davis, M.E., Rossi, J.J., and Behlke, M.A. (2005) Functional polarity is introduced by Dicer processing of short substrate RNAs. Nucleic Acids Res., 33:4140-4156.
* Supplement

Amarzguioui, M., Lundberg, P., Cantin, E., Hagstrom, J., Behlke, M.A., and Rossi, J.J. (2006) Rational design and in vitro and in vivo delivery of Dicer substrate siRNA. Nature Protocols, 1:508-517.

Marques, J.T., Devosse, T., Wang, D., Zamanian-Daryoush, M., Serbinowski, P., Hartmann, R., Fujita, T., Behlke, M.A., and Williams, B.R.G. (2006) A structural basis of discriminating between self and nonself double-stranded RNAs in mammalian cells. Nature Biotechnology, 24:559-565.
* Supplement

Collingwood, M.A., Rose, S.D., Huang. L., Hillier, C., Amarzguioui, M., Wiiger, M.T., Soifer, H.S., Rossi, J.J., Behlke, M.A. (2008). Chemical Modification Patterns Compatible with High Potency Dicer-Substrate Small Interfering RNAs. Oligonucleotides, 18:187-200.

Hefner, E., Clark, K., Whitman, C., Behlke, M.A., Rose, S.D., Peek, A.S., and Rubio, T. (2008) Increased potency and longevity of gene silencing using validated Dicer-substrates. J Biomolecular Techniques, 19:231-237.

For additional information and/or examples of use of these methods, see also:

Peek, A.S., and Behlke, M.A. (2007) Design of active small interfering RNAs. Curr. Opin. Mol. Ther., 9:110-118.

Amarzguioui, M., Rossi, J.J., and Kim, Dongho. (2005) Approaches for chemically synthesized siRNA and vector-mediated RNAi. FEBS Lett. 579:5974-5981.

Behlke, M. (2006) 27mer RNA Duplexes as Triggers of RNAi. BIOforum Europe, June 2006.

Behlke, M.A. (2006) Progress towards in vivo use of siRNAs. Mol Ther., 13:644-670.

Ramaswamy, M., Shi, L., Varga, S.M., Barik, S., Behlke, M.A., and Look, D.C. (2006) Respiratory syncytial virus nonstructural protein 2 specifically inhibits type I interferon transduction. Virology, 344:328-339.

Chu, T.C., Twu, K.Y., Ellington, A.D., and Levy, M. (2006) Aptamer mediated siRNA delivery. Nucleic Acids Res., 34:e73.

Lundberg, P., Welander, P.V., Edwards, C.K., van Rooijen, N., and Cantin, E. (2007) Tumor necrosis factor (TNF) protects resistant C57BL/6 mice against herpes simplex virus-induced encephalitis independently of signaling via TNF receptor 1 or 2. J. Virol., 81:1451-60.

Kim, M., Shin, D., Kim, S.I., and Park, M. (2006) Inhibition of hepatitis C virus gene expression by small interfering RNAs using a tri-cistronic full-length viral replicon and a transient mouse model. Virus Res. 122:1-10.